levels of leptin in cases with invasive breast cancer, patients with carcinoma in situ and control subjects were 10.4(±7.0), 8.7(±5.3) and 8.4 (±5.3 ng ml−1), respectively. The gene discussed is LEP; the disease is in situ carcinoma.